文献速递慢性肾脏病

慢性肾脏病3-4期口服镁补充剂的疗效、安全性及对血清钙化倾向的影响:一项前瞻性随机双盲安慰剂对照临床试验

Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity-A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial.
PubMed 文献 · Kidney Int Rep · 2016-12-30

结果显示口服镁补充剂安全且耐受性良好,30 mmol/d组T50显著延长40分钟,但细胞内镁未见升高。

要点

  • 口服镁补充剂在CKD 3-4期患者中安全且耐受性良好。
  • 元素镁30 mmol/d治疗8周可显著改善血清钙化倾向(T50)。
  • 尽管血清和尿镁升高,细胞内镁水平保持稳定。

核心结论

  • 口服镁补充剂在CKD 3-4期患者中安全且耐受性良好,并能改善血清钙化倾向(T50),但未增加细胞内镁。

主要发现

  • 尽管血清和尿镁显著增加,细胞内镁在整个试验期间保持稳定。
  • 在镁30 mmol/d组,8周后T50从256 ± 60分钟(均值±标准差)显著增加40分钟至296 ± 64分钟(95%置信区间,11-70,P < 0.05)。
  • 研究期间未报告与研究药物相关的严重不良事件。

临床怎么用

  • 对于CKD 3-4期患者,口服镁补充剂(尤其是元素镁30 mmol/d)可能安全地改善钙化倾向,但需进一步研究长期效果及对临床终点的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. Recent evidence suggests that increases in both serum and intracellular magnesium (Mg) can slow or even prevent the development of vascular calcification seen in CKD. Serum calcification propensity (T50) is a novel functional test, which is associated with all-cause mortality in CKD and measures the ability of serum to delay the formation of crystalline nanoparticles. Theoretically, increasing serum Mg should improve T50 and thereby reduce the propensity towards ectopic calcification. METHODS: We conducted a randomized placebo-controlled double-blinded clinical trial to investigate the safety of 2 different doses of oral Mg supplementation in subjects with CKD stages 3 and 4 as well as their effects on intracellular Mg and T50. Thirty-six subjects with CKD stages 3 and 4 were randomized to one of 3 groups (placebo, elemental Mg 15 mmol/d or elemental Mg 30 mmol/d) given as slow-release Mg hydroxide and followed for 8 weeks. RESULTS: Thirty-four subjects completed the trial. Intracellular Mg remained stable throughout the trial despite significant increases in both serum and urine Mg. T50 increased significantly by 40 min from 256 ± 60 (mean ± SD) to 296 ± 64 minutes (95% confidence interval, 11-70, P < 0.05) in the Mg 30 mmol/d group after 8 weeks. No serious adverse events related to the study medication were reported during the study. DISCUSSION: Oral Mg supplementation was safe and well tolerated in CKD stages 3 and 4 and improved T50, but did not increase intracellular Mg. Further studies are needed to investigate the long-term effects of Mg supplementation in CKD stage 3 and 4 and whether improvement in calcification propensity is related to clinical endpoints.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Bressendorff I, Hansen D, Schou M, et al. Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity-A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial. Kidney Int Rep. 2016. PMID: 29142966. doi:10.1016/j.ekir.2016.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。